Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 16,834 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Symptom Clusters Clear all

Conditions: Dry Eye
Interventions: SYSTANE Ultra, Optive; Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Fibromyalgia Syndrome
Interventions: Lacosamide, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more

Conditions: ACS - Acute Coronary Syndrome
Interventions: Sponsor MCG deivce; Device
Lead sponsor: SB Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infection, Tobacco-Related Carcinoma
Interventions: Computed Tomography, Smoking Cessation Intervention; Procedure · Behavioral
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 45 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: doxercalciferol; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Neoplasms
Interventions: Alectinib, Crizotinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Orange, California • Boston, Massachusetts

Conditions: Colonic Polyps, Polyposis Coli, Colorectal Cancer
Interventions: Not listed
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 2,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Alere q HIV-1/2 Detect for point of care infant testing, GeneXpert HIV-1 Qual for point of care infant testing, HIV DNA PCR testing (Standard of Care); Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hereditary Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 39
States / cities: Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more

Conditions: HIV Infections, Sexually Transmitted Diseases, Stigma, Social
Interventions: Information Resources, Social Support, HIV Testing; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 15 Years to 29 Years · Male only
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Sepsis, Septic Shock, Sepsis Syndrome, Sepsis Bacterial, Sepsis, Severe, Sepsis Bacteremia
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis, Acute Lymphoblastic Leukemia, Chronic Myelocytic Leukemia, Non Hodgkins Lymphoma, Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions: TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day; Drug
Lead sponsor: Tarix Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hydration Status
Interventions: Hydration education and self-assessment; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Celiac Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 2 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions: Zumba High Tempo, Zumba Low Tempo; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: HIV Infections
Interventions: Levocarnitine, Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Foster City, California

Conditions: Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Luminex Corporation; Industry
Eligibility: 1 Day to 7 Days
Enrollment: 7,462 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Albany, New York • Nashville, Tennessee • Taylorsville, Utah

Conditions: Chronic Graft-versus-host-disease
Interventions: axatilimab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 11
States / cities: Birmingham, Alabama • Duarte, California • Miami, Florida + 8 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Haplo-Cord Transplant, Matched Unrelated Donor Transplant; Biological · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: COVID-19
Interventions: OP-101, Placebo; Drug
Lead sponsor: Ashvattha Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more

Conditions: Atrophy, Sepsis, Weakness
Interventions: Not listed
Lead sponsor: Gregory A. Schmidt; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infection
Interventions: Different formulations of once-daily lopinavir/ritonavir; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 5
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 2 more

Search by objective public record fields.

Evaluation of SYSTANE Ultra Lubricant Eye Drops

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin

Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Non-Invasive Prediction of Colorectal Neoplasia

Piloting At-birth Point of Care HIV Testing Strategies in Kenya

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

Function of Circulating Exosomes in Sepsis-induced Immunosuppression

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

The Impact of Self-assessment on Hydration

Gut Permeability Assessment in Celiac and Gluten Sensitive Children

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

Clinical Evaluation of NeoPlex4 Assay and NeoPlex System

A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Integrating PrEP Into Family Planning Services at Title X Clinics in the Southeastern US

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

Muscle Atrophy in Sepsis

A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules